ライフサイエンスコーパス: median

1 uartile range: 1.05-1.35) and 0.76 +/- 0.49 (median: 0.7; interquartile range: 0.4-1.15) vs. 3.63 +/-

2 uartile range: 3.25-3.55) vs. 1.23 +/- 0.23 (median: 1.2; interquartile range: 1.05-1.35) and 0.76 +/

3 operative (18)F-FET PET (time after surgery: median, 14 d; range, 5-28 d) were included.

4 were diagnosed before the age of 40 months (median, 16 months; interquartile range, 9-29 months).

5 ed to have higher prevented fractions (group median 17.9% [12.3-20.5]) than high-income countries (14

6 her peak intensities for the precursor ions (median: 18 times in negative mode and 210 times in posit

7 m vs. 8.6 mm) and located closer to foveola (median, 2.0 mm vs. 2.8 mm) than those treated with the 1

8 nt, 21.4%; SD, 16.5%; range, -3.2% to 74.4%; median, 20.1%).

9 0.001) but longer cold ischemic time (CIT) (median 21.0 h versus 18.6 h, P < 0.001).

10 ) who had preoperative (time before surgery: median, 23 d; range, 6-44 d) and postoperative (18)F-FET

11 ter in OT compared to both untrained groups (median (25-75%): MU: 0.065 (0.049-0.080); OU: 0.085 (0.0

12 ma of children and adults was 3.37 +/- 0.34 (median: 3.4; interquartile range: 3.25-3.55) vs. 1.23 +/

13 quartile range: 0.4-1.15) vs. 3.63 +/- 0.29 (median: 3.7; interquartile range: 3.45-3.8), respectivel

14 r in outpatients compared with other groups (median 30% [IQR 0-40%], 44% [31-70%] and 70% [50-88%], p

15 dneys with lower Kidney Donor Profile Index (median 30% versus 35%, P < 0.001) but longer cold ischem

16 of the 132 probands with genetic diagnoses (median, 31.5 years) was about 14.5 years earlier than th

17 ventilation-perfusion mismatch was elevated (median, 34% [32-45%] of lung units) and, in six out of s

18 hout molecular diagnoses (i.e. non-carriers, median 46.0 years).

19 During follow-up (median 516 days), the combined endpoint of cardiovascula

20 After 12.8 y (median), 6378 participants had experienced a CHD event.

21 55% vs 33%, P = 0.03) and more publications [median 70 (interquartile range, IQR 55-100) vs 40 (IQR 2

22 Twenty adults (median 71 years) with an established diagnosis of glauco

23 Samples were obtained before and after (median=82 days) left ventricular assist device implantat

24 ration of patients was 19.2 +/- 21.3 months (median, 9 months; range, 1-58 months).

25 quencing method achieved very high coverage (median 99%), specificity (99.8%) and sensitivity (90% fo

26 Median absolute error of TimeSignature was higher in ind

27 We developed equations to estimate the median ACR from a PCR, optionally including specified co

28 Median adherence over 3 months was 74% +/- 21% (+/-stand

29 The median adjusted Ct value for asymptomatic children was 1

30 patients (mean age 55 +/- 14 yr, 28.5% male, median admission Glasgow Coma Scale 14 [10-15]) were ana

31 after the detection of a dnDSA, 65.3 months (median) after kidney transplantation.

32 ed 252 participants (210 vaccine/42 placebo; median age 23 years; 43% female) between 9 February 2015

33 During the study period, 306 pregnant women (median age 29 years, 52.9% Hispanic or Latino) with CVD

34 In sum, 23 227 patients (58% female; median age 34 years [interquartile range 28-41]) were AR

35 sufficient data for this report (78% female; median age 47 years; median body mass index 46 kg/m).

36 The 231 included IE cases (187 [81%] men, median age 62 years, 153 [66%] native valves) comprised

37 163 formalin-fixed paraffin-embedded (FFPE, median age 67, 39% women) samples, respectively.

38 Of 614 patients (median age 69 years, (IQR 25) and 62% male), 381 (62%) h

39 na, Spain and included 112 fresh frozen (FF, median age 69, 44% women) and 163 formalin-fixed paraffi

40 Fifty participants (median age 7.3 years) were randomized and initiated trea

41 The pooled sample included 252 745 women (median age at baseline, 57 years) with 38% self-reportin

42 Median age at dialysis initiation was 64 years, 45% were

43 Median age at HCT was 1.2 years.

44 Median age at ITx was 7.7 years and weight was 23 kg.

45 INSTIs were 81% male and 50% nonwhite with a median age at switch of 50 years, CD4+ T-cell count 512

46 3 (44.1%) individuals aged <=17 years with a median age of 19 years (interquartile range, 10-32); 423

47 ht eyes (96 children) were identified with a median age of 2.5 months (range, 1-7 months) at the time

48 in 30 (53%) of 57 affected individuals at a median age of 22.5 years.

49 All patients were white females, with a median age of 27 years (range 21-75) at diagnosis.

50 Ninety patients were analyzed with a median age of 57 years.

51 A total of 480,940 middle-aged adults (median age of 58 years [range 38-73], 46% male, 95% whit

52 Fifty-one patients with a median age of 72 years (range, 63-80 years) were include

53 The median age of cases was 49.5 years (interquartile range

54 The median age of diagnosis was 15 months (range; 5 months-1

55 The median age of enrolled participants is 21 years (range 0

56 The median age of the patients was 30 years and the male to

57 At enrolment, the median age was 15 years (IQR 14-17), 52% of adolescents

58 Median age was 35.5 years (range, 3-88).

59 Median age was 40 years (IQR 35-48), CD4 cell count was

60 Median age was 46 years (range 18 to 90 years), 68/106 (

61 The median age was 49 (range, 18-86) years, and 62% were >=

62 Among 7770 participants enrolled, the median age was 50 years, 31% were female (natal sex), 43

63 Median age was 62 years, and 85% were men.

64 s encephalitis occurred in younger children (median age, 1.7 years [interquartile range {IQR}, 0.1-6.

65 2 infants hospitalized for RV bronchiolitis (median age, 4 months), we identified 4 distinct endotype

66 rosarcoma received ivosidenib (women, n = 8; median age, 55 years; range, 30-88 years; 11 had receive

67 ective study included 208 patients with SSc (median age, 57 years; 167 women) evaluated between Janua

68 Results: There were 75 men (median age, 69 y; median serum PSA, 3.69 mug/L) with 232

69 record abstractions and available ICD codes (median age, 69 years [interquartile range, 54 to 81 year

70 compared with immune-mediated encephalitis (median age, 7.6 years [IQR, 4.6-12.4]).

71 ol), and repair (regenerating gene 1beta) at median ages 3, 14, and 28 months.

72 Median ages for the cohorts ranged from 41.5 to 59.0 yea

73 was performed using an automated algorithm (median analyzed duration [quartile 1-quartile 3]: 78.3 [

74 glioma-bearing animals and further increased median and overall survival when combined with anti-PD-1

75 The median angiographic diameter stenosis of the randomized

76 With climate change, the median annualized impact exceeds pound 100m.yr(-1).

77 Median aortic annulus area and perimeter were 617 mm(2)

78 The median area under the curve (AUC0-24 h) after day 7 and

79 %]), prescriptions lasting more than 7 days (median ARI, 4.5%), and higher morphine milligram equival

80 a persistent motor that sustains attachment (median attachment duration >3 s) at high forces (5 pN).

81 esin can switch from a fast detaching motor (median attachment duration <0.2 s) to a persistent motor

82 flat-dosing), flat-dosing resulted in higher median AUC0-24h compared to the weight-band dosing.

83 of 99 in the non-randomised cohort died; the median baseline CD4 count for participants who died was

84 , median total area of GA was 13.4 mm(2) and median BCVA was 43 letters in the intervention eye.

85 Median BLL was significantly higher in 45- to 60-year-ol

86 black or African American and 15% Asian, the median body mass index (calculated as calculated as weig

87 women (59%), African American (68%), obese (median body mass index 41), and hypertensive (98%), with

88 his report (78% female; median age 47 years; median body mass index 46 kg/m).

89 credible interval = 2.4-5.5), with a higher median but overlapping credible intervals compared with

90 Median C-reactive protein [138 mg/L (IQR: 83-179) vs 73

91 counting for the costs of failed trials, the median capitalized research and development investment t

92 height in meters squared) was 25.8, and the median CD4 cell count 620/uL.

93 Median center outcome rates were 72.6% LT, 18.2% died/to

94 countries, with a resulting age-standardized median CFR of 1.9%.

95 Median clinical follow-up lasted 95 months (range, 8-219

96 M. muris pretreatment decreased the median colonization density of NTHi from 6 x 10(5) CFU/m

97 mples, ECl-OPEs and Enonchlorinated-OPEs had median concentrations of 4.5 and 2.5 ng g(-1), respectiv

98 illness information for 395 patients, with a median cost of illness per case of $59.99 (IQR, $24.04-$

99 traumatic terminal ileal perforation, with a median cost of illness per case of US $196.37 (IQR, US $

100 was amenable to surgical/ablative treatment, median CSS was significantly superior compared to chemot

101 Median daily step count was similar among men (7202 with

102 th PNI had worse DFS at univariate analysis (median DFS: 20 vs 15 months, P < 0.01).

103 e placebo group (P = .29), with an estimated median difference of -0.04 (95% CI,-0.18 to 0.11) minute

104 The median distance between the donor hospital and transplan

105 verse relationship between Diez Roux SES and median distance traveled (90 versus 80.1 versus 60.5 ver

106 were treated with definitive chemoradiation (median dose 50.4 Gy) followed by resection within 4 mont

107 The results show that the median dose area product (DAP) for CVAD insertion is 0.7

108 Ribavirin was given at the median dose of 600 (range, 29-1200) mg/day (mean, 8.6 +/

109 of 0.21 than the usual-oxygen group, with a median duration of 29 hours (interquartile range, 5 to 7

110 ) mg/day (mean, 8.6 +/- 3.6 mg/kg/day) for a median duration of 3 (range, 0.25-18) months.

111 Median duration of cardiopulmonary bypass was 4.6 hours

112 e study: 806 in the negative pressure group (median duration of negative pressure, 4 days) and 802 in

113 ; 19 of 54 patients) in the EZH2(WT cohort.) Median duration of response was 10.9 months (95% CI 7.2-

114 Among 45 responders, the median duration of response was 8.0 months (95% CI 6.5-1

115 The primary outcome, median duration with Spo2 of less than 90%, was 0.7 (int

116 um samples from 146 patients with severe AD (median Eczema Area and Severity Index = 28.3; interquart

117 Median estimated glomerular filtration rate (eGFR) was 4

118 Results: Median estimated survival was 5.7 mo for (177)Lu-PSMA al

119 Median exposure (dose area product/kg) was decreased by

120 elatively low estimated inhibition levels at median exposure levels may explain why no relationship b

121 For apixaban 2.5 mg twice daily, the median exposure was 2780 ng/(mL.h) for patients with CrC

122 The median extracorporeal membrane oxygenation support time

123 Median extraction time (low=0 versus high grade=97 secon

124 ratios relative to the long-term population median F/alpha.

125 Median follow-up after diagnosis was 34 months (IQR: 17

126 Median follow-up among survivors was 11 years.

127 Median follow-up at the time of data cutoff was 2.3 mont

128 At the median follow-up of 1 year, high-certainty evidence show

129 Over a median follow-up of 10.2 years, mortality was highest fo

130 After a median follow-up of 11 years (range 1 mo-25 yrs), sympto

131 At a median follow-up of 12 months, the objective response ra

132 At a median follow-up of 12.3 months (range, 7.0 to 32.3), 57

133 zed trial conducted from 2008 to 2012 over a median follow-up of 17.0 months in 966 sites (52 countri

134 At a median follow-up of 18 months, overall survival was 95%

135 At a median follow-up of 24.2 months in treatment-naive patie

136 87 eyes of 54 patients were assessed with a median follow-up of 28 months.

137 As of July 2, 2019, at a median follow-up of 28.4 months (IQR 17.7-36.8), median

138 After a median follow-up of 3.1 years, the achieved LDL-C concen

139 ohort study within the PREDIMED Study during median follow-up of 3.8 y.

140 At a median follow-up of 31.4 mo, median overall survival was

141 After a median follow-up of 42 months (IQR 22-67), 33 (28%) of t

142 During a median follow-up of 43 (3-57) months after DAA start, 36

143 With a median follow-up of 44 months (26-53), 4-year event-free

144 During median follow-up of 5.4 (IQR 5.1-5.9) years, 8828 partic

145 Another 11 patients with a median follow-up of 54 months (range, 15-138 months) wer

146 At a median follow-up of 6.6 years, there were 8 major advers

147 At a median follow-up of 70 months, rates of 5-year overall s

148 At a median follow-up of 71.5 months (IQR 71.3 to 71.7), the

149 The study included 432 patients with a median follow-up of 8.65 years.

150 L of which 371 (36%) received an RT during a median follow-up period of 2.5 (1.4-4.1) years.

151 At the data cutoff (Aug 7, 2019), the median follow-up period was 12.9 months (IQR 6.2-22.9).

152 During a median follow-up time of 62.5 months, 564 of the 3,478 p

153 After a median follow-up time of 696 days (interquartile range 1

154 Over a median follow-up time of 7 years, 74 of 103 treated pati

155 Median follow-up was 13.2 months (IQR 7.3-20.4) as of da

156 Median follow-up was 15.8 years.

157 The median follow-up was 17.8 months (IQR 11.6-21.3).

158 Median follow-up was 19.0 months (IQR 15.0-23.4).

159 Median follow-up was 30 days (IQR 27-83).

160 Median follow-up was 38.3 months (IQR 20.7-46.1, range 0

161 The median follow-up was 44 mo.

162 ed eighty-five patients were included with a median follow-up was 5.8 years.

163 The median follow-up was 59 months, and overall and major re

164 253 clinically stable COPD patients (4-year median follow-up).

165 evaluated, with follow-up through May 2018 (median follow-up, 2.63 years).

166 ciated with incident ASCVD (n = 1386 events; median follow-up, 25.2 years; hazard ratio [HR], 1.06 [9

167 At 96 months median follow-up, 94% versus 12% remained MRD free.

168 With a 2.9-year median follow-up, OS improved from 33% (46-68%) for HCT

169 The median frequency of RSV-F-specific interferon gamma-secr

170 g/dL; median triglycerides level, 240 mg/dL; median HDL-C level, 36 mg/dL; and median high-sensitivit

171 By survival curve analysis median healing time for cure was 102 for Sb v group and

172 240 mg/dL; median HDL-C level, 36 mg/dL; and median high-sensitivity C-reactive protein level, 2.1 mg

173 Over a median hospital length of stay of 7 days (interquartile

174 The median hospital stay was 1 to 9 days across specialties.

175 Median hospital-level risk-adjusted 30-day home time was

176 hey had an IFNgamma signature lower than the median (HR 0.88 [95% CI 0.40-1.93], p=0.74).

177 lasted 95 months (range, 8-219 months), and median imaging follow-up lasted 41 months (range, 0-189

178 , depletion of AP factors, or AH50 less than median, impaired in vitro serum control of KP that was r

179 The median injected activity of (18)F-rhPSMA-7 was 327 MBq (

180 At baseline, median intake of SSBs was 472.1 mL/wk (IQR: 198.8-1416.4

181 The median inter-site MAP variability was 6mmHg with an inte

182 The median (interquartile range) follow-up time was 4.6 (2.7

183 ll postoperative days [area under the curve: median (interquartile range) pg/mL: 3285 (1697-6179) vs

184 loping CPC vs no-CPC (area under the curve), median (interquartile range): 5196 (1823-9061) vs 1934 (

185 who needed endotracheal intubation (n = 12) (median [interquartile range], 11 [8-15] cm H(2)O vs. 31.

186 dex surgery was significantly lower for EVR (median [interquartile range]: $25 924 [$22 280-$32 556]

187 Median (IQR) concentration of plasma TMAO was 3.05 mumol

188 Median (IQR) psychological stress scores were significan

189 n the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR, 1.02 [95% C

190 The median(IQR) duration of exposure to BDQ and DLM was 77(4

191 er order assemblies containing 40 molecules (median) (IQR: 23, 87) of 5-LO, and 53 molecules (62, 156

192 0 versus high grade=97 seconds, P<0.001) and median laser pulsations delivered (low=0 versus high gra

193 Median lead time between ctHPVDNA positivity and biopsy-

194 automated perimetry and arranged in series (median length and duration, 9 VFs over 48 months).

195 arfarin-associated major bleeding had longer median length of stay (11 vs 6 d; p = 0.02), and higher

196 as elective or non-urgent for 362 (90%), and median length of stay [Q1, Q3] was 5.1 days [1.9, 9.9].

197 The median lifetime number of male sexual partners was 17 (I

198 8.5%, OR 0.80, 95% CI 0.56-1.15, P = 0.23), median LOS (equivalent at 7 days, P = 0.09), reoperation

199 to 3 groups according to variations in their median LOS as follows: major decrease, moderate decrease

200 Median LOS was 4 days and 34% of patients experienced co

201 5 [9.0] years; 35% women; 70% with diabetes; median low-density lipoprotein [LDL] cholesterol level,

202 (IFN-gamma, IL-2, and TNF), with the highest median magnitude detected after the second dose of vacci

203 73.7%, the median MLA was 2.9 mm(2), and the median maximum lipid plaque content was 33.4%.

204 One eye each of 97 glaucoma patients (median mean deviation, -2.31 dB) and 65 control particip

205 mpling times 0 to 56 days post-positive PCR (median/mean, 2/6.2 days).

206 cterized by a female/male ratio of 3.9 and a median (minimum-maximum) age at diagnosis of 62 (18-82)

207 VUS, the median plaque burden was 73.7%, the median MLA was 2.9 mm(2), and the median maximum lipid p

208 At baseline, median MRI-PDFF was 16.3% and MRE-stiffness was 3.27 kPa

209 h prior stroke had a higher stroke severity (median National Institutes of Health Stroke Scale, 11 [6

210 us and neuroimaging, which were favored over median nerve somatosensory evoked potentials for prognos

211 s with MSI colorectal cancer revealed that a median number of 31 FSPs out of the 209 encoded by the v

212 The median number of excised nodes was 21 (interquartile ran

213 Using an optimistic prior, posterior median odds ratios were 0.61 (95% credible interval, 0.4

214 TLV-1 carriers who remained ATL-free after a median of 10 years of follow-up.

215 MSM initiated PrEP through the study after a median of 122 days.

216 8 incident CVD events and 1209 deaths over a median of 13.0 y.

217 Auditory distractions occurred a median of 138 times per case [interquartile range (IQR)

218 gnancy (cumulative incidence of 7.4% after a median of 19 months), inflammatory disorders (VTE risk i

219 lowed-up until discharge from hospital for a median of 2 days (IQR 1-4).

220 administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%.

221 Prior to hospital-diagnosis (median of 32 days), 45.1% of patients had one or more vi

222 orts after PS matching, respectively) with a median of 4.6 years of follow-up.

223 sitive children with serial MRI scans over a median of 5 years from presentation.

224 e assessed by stress CMR and followed over a median of 5.4 years.

225 ricular ejection fraction above or below the median of 57%.

226 r withdrawn more frequently over time with a median of 58% (interquartile range, 39-89%).

227 osis-associated healthcare visits occurred a median of 6 months after diagnosis.

228 alent COPD, 98 (4.3%) had incident COPD at a median of 6.2 years.

229 tients (53.3%) had hCG normalization after a median of 9 avelumab cycles; none subsequently relapsed.

230 o the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or

231 We assessed 100 adult HCT recipients a median of 9.3 years (range: 1.7-40) after transplant.

232 , distant (n = 3), and combined (n = 3)-at a median of 9.8 months from diagnosis (range, 8.9-13.7 mon

233 ght patients developed EBV reactivation at a median of 96 days with no incidence of lymphoproliferati

234 ine coagulation biomarker levels at or above median of the entire study population, ranging from 4.2%

235 cluding effects of land use and the ensemble median or mean compares better to observational datasets

236 Median OS (mOS) was 3.3 months in the ITT population.

237 Median OS was 13 months (95% CI 10-18) for patients with

238 Median overall survival (OS) was 18 months (95% CI, 8-27

239 rogen-deprivation therapy resulted in longer median overall survival than placebo plus androgen-depri

240 At a median follow-up of 31.4 mo, median overall survival was 13.3 mo (95% CI, 10.5-18.7 m

241 In the high PD-L1 population, median overall survival was 14.4 months (95% CI 10.4-17.

242 Median overall survival was 57.1 months (95% CI 50-72) i

243 The median parenchyma-absorbed dose was 37 Gy (range, 12-55

244 ng 1396 total preoperative MRI examinations (median patient age, 56 years; range, 25-94 years), resul

245 The global median PFP was 15.0% (range 6.6-20.5), conservatively eq

246 -random assignment follow-up of 13.5 months, median PFS was longer with continuous versus 1-year fixe

247 and had less severe clinical presentations (median Pitt score, 0 [interquartile range {IQR} 0-1] vs

248 .6%; by near-infrared spectroscopy-IVUS, the median plaque burden was 73.7%, the median MLA was 2.9 m

249 (71%) organs, that were transplanted after a median preservation time of 18 h, with 100% 90-day survi

250 Median procedure duration was 80 minutes.

251 nths in relapsed or refractory patients, the median progression-free and overall survival times were

252 er-operating-characteristic analyses using a median progression-free survival (PFS) of >= 9 mo and ov

253 im overall survival analysis (May 31, 2019), median progression-free survival in the intention-to-tre

254 vival at the overall survival database lock, median progression-free survival remained significantly

255 13.0 months (5.6-NE) in the EZH2(WT) cohort; median progression-free survival was 13.8 months (10.7-2

256 Median progression-free survival was 13.93 months (95% C

257 Median progression-free survival was 14.5 months (95% CI

258 nostic features of the cohort included short median PSA doubling time (2.3 mo) and extensive prior tr

259 preservation of serviceable hearing based on median pure tone averages (PTA), and procedure-related a

260 Anatomic structures were segmented, and median R2* values were calculated in the neocortex and c

261 Median (range) refraction OD/OS was +0.88/+1.25 (-8.75 t

262 h care facility and/or hemin administration (median [range] annualized attack rate 2.0 [0.0-37.0]).

263 ion in rates across hospital sites (adjusted median rate, 11.4%; IQR, 8.9-14.5).

264 the nivolumab plus ipilimumab group, whereas median recurrence-free survival was 12.4 months (95% CI

265 an follow-up of 28.4 months (IQR 17.7-36.8), median recurrence-free survival was not reached in the n

266 Among children <5 years old, there was a median reduction of 59% (IQR, 46-74) in rotavirus hospit

267 oms after receiving palliative liver RT with median response duration of 3 months.

268 esults: There were 75 men (median age, 69 y; median serum PSA, 3.69 mug/L) with 232 metastatic nodes

269 The sensitivity analysis using the reported median showed a greater monetized benefit of $10,658 (Ad

270 = 282; cT1b, n = 25; size range, 0.6-6.5 cm; median size, 2.5 cm) underwent cryoablation with CT (n =

271 Observed median steady-state TFV-DP was 965 fmol/punch (IQR:691,

272 The CCR2 antagonist CCX872 increased median survival as a monotherapy in KR158 glioma-bearing

273 cleaved caspase-3, and leads to a prolonged median survival of the mice (36.5 vs. 22.5 d, respective

274 leading cause of cancer-related death with a median survival time of 6-12 months.

275 Median survival was not reached, 49 and 17 months for 0,

276 vity, and antigen-site density most impacted median survival.

277 The median SUV(max) across all lesions was 11.6 (range, 1.5-

278 treated with the 10-mm plaque were smaller (median thickness, 1.9 mm vs. 2.6 mm; LBD, 7.1 mm vs. 8.6

279 7 was measured repeatedly for up to 6 years (median three samples per person, median time from first

280 Median time between first and reinfection swab was 64.5

281 Median time between successful contacts was 3.0 (IQR, 3.

282 The median time between vitreoretinal surgery and orbital em

283 The cohort included 163 patients with median time from discharge to last recorded follow-up of

284 to 6 years (median three samples per person, median time from first to last sample, 4.3 years).

285 red repeat intervention for IOP control with median time of 3.17 years (IQR, 0.92-6.56) from first su

286 The median time since polycythaemia vera diagnosis was 8.2 y

287 The median time to alleviation of symptoms was 79.0 hours fo

288 er 1000 textured implants (1 in 871), with a median time to diagnosis of 10.3 years (range, 6.4-15.5

289 The median time to parasitemia was significantly shorter in

290 ent cases of breast cancer during follow-up (median time: 5.2 years).

291 At baseline, median total area of GA was 13.4 mm(2) and median BCVA w

292 Median treatment duration was 5.3 years.

293 protein [LDL] cholesterol level, 75.0 mg/dL; median triglycerides level, 240 mg/dL; median HDL-C leve

294 Median TTR for major respiratory pathogens by organism r

295 Mean age was 74 years, with a median type 2 diabetes duration of 16 years.

296 A-7 was 327 MBq (range, 132-410 MBq), with a median uptake time of 79.5 min (range, 60-153 min).

297 Patients in the 2020 cohort showed worse median VA at presentation (1.00 logarithm of the minimum

298 Median VA of the better-seeing eye at final study visit

299 ly , the estimated reproduction number has a median value larger than one, although with a wide dispe

300 Median z scores did not improve in contralateral homolog